BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Bausch & Lomb (BOL) Enters Into Definitive Agreement With Technolas Perfect Vision Acquiring an Option to Purchase Company


9/8/2011 9:03:40 AM

ROCHESTER, NY and MUNICH, GERMANY--(Marketwire - September 08, 2011) -

Bausch + Lomb, the global leader in eye health, and Technolas Perfect Vision GmbH (TPV), a leading ophthalmology laser company, have entered into a definitive agreement providing Bausch + Lomb with an option to purchase all outstanding and unowned TPV shares for a total company value of up to EUR 450 million, based on the achievement of certain milestones and earnouts. TPV was established in 2009 through a joint venture between Bausch + Lomb and 20/10 Perfect Vision AG to develop and sell advanced refractive and cataract technologies.

"We have tremendous confidence in TPV's femtosecond laser technology and the company's ability to deliver a platform that will meet the needs of doctors and patients well into the future," said Brent Saunders, chief executive officer of Bausch + Lomb.

As previously announced, Bausch + Lomb and TPV will promote and further advance femtosecond laser platforms worldwide.

About Femtosecond Lasers
Femtosecond lasers emit optical pulses of extremely short duration in the domain of femtoseconds, as short as one-quadrillionth of a second. These ultrashort pulses are too brief to transfer heat or shock to the material being cut and can make surgical incisions with extreme precision.

About Bausch + Lomb
Bausch + Lomb is one of the best-known and most respected healthcare companies in the world. Its core businesses include contact lenses and lens care products, ophthalmic surgical devices and instruments, and ophthalmic pharmaceuticals. Founded in 1853, the company is headquartered in Rochester, N.Y., and employs more than 10,000 people worldwide. Its products are available in more than 100 countries. More information is available at www.bausch.com.

About Technolas Perfect Vision
Technolas Perfect Vision GmbH is a leading ophthalmology laser company, formed through a joint venture between Bausch + Lomb, and 20/10 Perfect Vision AG. TPV has a full range of expertise in both femtosecond and excimer businesses, with current innovations focused on laser cataract surgery and the correction of presbyopia. More information is available at www.technolaspv.com and www.better-reading-vision.net.


News Media Contacts:
Michelle McAdam
Bausch + Lomb
(949) 297-3546
Email Contact

Elizabeth Murphy
Bausch + Lomb
(585) 338-8528
Email Contact

Digg this    Bookmark with del.icio.us    Add to Newsvine

Technorati:



Read at BioSpace.com
Read at News Release

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES